IN2013MN01218A - - Google Patents

Download PDF

Info

Publication number
IN2013MN01218A
IN2013MN01218A IN1218MUN2013A IN2013MN01218A IN 2013MN01218 A IN2013MN01218 A IN 2013MN01218A IN 1218MUN2013 A IN1218MUN2013 A IN 1218MUN2013A IN 2013MN01218 A IN2013MN01218 A IN 2013MN01218A
Authority
IN
India
Prior art keywords
charge
drugs
designing
biopolymers
synthesizing
Prior art date
Application number
Inventor
Boris Slavinovich Farber
Sofya Borisovna FARBER
Artur Viktorovich Martynov
Original Assignee
Boris Slavinovich Farber
Sofya Borisovna FARBER
Artur Viktorovich Martynov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boris Slavinovich Farber, Sofya Borisovna FARBER, Artur Viktorovich Martynov filed Critical Boris Slavinovich Farber
Publication of IN2013MN01218A publication Critical patent/IN2013MN01218A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Food Science & Technology (AREA)
  • Computing Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The invention can be used in medicine and veterinary science for designing (creating and synthesizing) therapeutic and preventive drugs which are effective in the treatment of cancerous and viral diseases in humans and animals as well as for designing new drugs. The novel method for designing and synthesizing therapeutic and preventive drugs is characterized in that a target biopolymer (protein DNA RNA or a combination thereof) is identified and subsequently used as a ligand having been cleaved into oligomer fragments (by nucleases synthetic nucleases and proteases) which are modified by replacing the charge thereof with an opposite charge (by acylation with dicarboxylic acid anhydrides or alkylation with halogen carboxylic acids); the same target biopolymer is also used as a ligand having been modified by the partial replacement of the charge of the molecule with an opposite charge to form a supramolecular ensemble of biopolymers. A supramolecular ensemble of oligomers is used wherein the oligomers are products of the hydrolysis of biopolymers and the charge of the oligomer molecules is replaced with an opposite charge or in the case of the whole biopolymers is partially altered. By using this method it is possible to significantly reduce the costs of designing and synthesizing new drugs broaden the spectrum of action of existing genetically engineered protein drugs and create new classes of dynamic therapeutic and preventive drugs that self adapt to an organism and a target.
IN1218MUN2013 2010-11-22 2010-11-22 IN2013MN01218A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2010/000694 WO2012070968A1 (en) 2010-11-22 2010-11-22 Method for the molecular design and synthesis of therapeutic and preventive drugs

Publications (1)

Publication Number Publication Date
IN2013MN01218A true IN2013MN01218A (en) 2015-06-12

Family

ID=46065142

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1218MUN2013 IN2013MN01218A (en) 2010-11-22 2010-11-22

Country Status (5)

Country Link
US (1) US20120130699A1 (en)
EP (1) EP2644617A4 (en)
EA (1) EA025399B1 (en)
IN (1) IN2013MN01218A (en)
WO (1) WO2012070968A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527142A1 (en) 2011-05-24 2012-11-28 Cryovac, Inc. Multilayer polyester film for ready meals
US20140220556A1 (en) * 2013-02-06 2014-08-07 Artur Martynov Method of Design and Synthesis of a New Drug
RU2646885C1 (en) * 2017-02-15 2018-03-12 Владимир Николаевич Коваль Oligopeptide composition
EA202090767A1 (en) * 2018-05-04 2020-08-03 Борис Славинович ФАРБЕР PHARMACEUTICAL COMPOSITION BASED ON POLYMYXIN FOR TREATMENT OF INFECTIOUS DISEASES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5495423A (en) 1993-10-25 1996-02-27 Trustees Of Boston University General strategy for vaccine and drug design
AUPN741696A0 (en) * 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
US5854992A (en) 1996-09-26 1998-12-29 President And Fellows Of Harvard College System and method for structure-based drug design that includes accurate prediction of binding free energy
ES2285774T3 (en) 1997-06-02 2007-11-16 The Johns Hopkins University INFORMATIC PROCEDURE USING FREE ENERGY CALCULATIONS FOR THE DESIGN OF LIGANDS AND THE PREACHING OF UNION TARGETS.
US7396919B1 (en) * 1998-07-17 2008-07-08 Mirus Bio Corporation Charge reversal of polyion complexes
US20030088366A1 (en) * 2001-07-13 2003-05-08 Neurocrine Biosciences, Inc. Computational method for the design of screening libraries for superfamilies of molecular targets having therapeutic utility
US20040167090A1 (en) * 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
US7365058B2 (en) * 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same

Also Published As

Publication number Publication date
EA201300490A1 (en) 2014-03-31
WO2012070968A1 (en) 2012-05-31
US20120130699A1 (en) 2012-05-24
EA025399B1 (en) 2016-12-30
EP2644617A1 (en) 2013-10-02
EP2644617A4 (en) 2014-05-14

Similar Documents

Publication Publication Date Title
MX2009012650A (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders.
EA201591281A1 (en) RIBONUCLEIC ACIDS WITH 4'-THIOMODIFIED NUCLEOTIDES AND RELATED METHODS
EP4273782A3 (en) A system, device and a method for providing a therapy or a cure for cancer and other pathological states
BR112012029588A2 (en) her3-related biological materials.
IN2014DN05670A (en)
IN2013MN01218A (en)
MX2009008139A (en) 2-5a analogs and their methods of use.
MX361728B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen.
MX345316B (en) Methods and compositions for diagnosis and treatment of cancer.
MX2009003729A (en) Rna antagonist compounds for the modulation of pcsk9.
CO2022003552A2 (en) Multispecific binding proteins for cancer treatment
NO20054769D0 (en) Substituted phenylalkanoic acids
DE602006020501D1 (en) SYNTHETIC MECP2 SEQUENCE FOR PROTEIN SITE THERAPY
EA201491726A1 (en) CONJUGATES OF BORONIC ACIDS OF OLIGONUCLEOTIC ANALOGS
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
BR112018006687A2 (en) disease prevention, treatment and reversal using therapeutically effective amounts of active fatty acids
MX2017001898A (en) Mannose-6-phosphate bearing peptides fused to lysosomal enzymes.
CR20240003A (en) Novel therapeutic delivery moieties and uses thereof
PE20110053A1 (en) PRODUCTION PROCESS OF ACIDULATED 50% CONCENTRATED SOLUTION AND DRY PEPTIDE POWDER, FROM PRODUCTS AND PROTEIN RESIDUES OF ANIMAL ORIGIN, FISHERIES AND AQUACULTURE
EA201390867A1 (en) COMPOSITIONS BASED ON CLAY AND LEATHER, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION IN FOOD AND THERAPEUTIC TREATMENT
EA200701694A1 (en) Enzymatic Vitamin C Preparation
UY32830A (en) PROCEDURES FOR THE STEREOSELECTIVE SYNTHESIS OF BICYCLIC HETEROCYCLES
BR112015010512A2 (en) 3-aminocyclopentane carboxamide derivatives
EA201300489A1 (en) Modified anti-complex oligonucleotides with anti-cancer properties and method for their production
SE1750774A1 (en) Novel nucleic acid molecules and their use in therapy